PCM 075

Drug Profile

PCM 075

Alternative Names: NMS-1286937; NMS-P937; PCM075

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; TrovaGene
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Dec 2017 Efficacy data from a phase II trial in Acute myeloid leukaemia released by TrovaGene
  • 07 Dec 2017 Pharmacodynamics data from preclinical studies in Cancer released by Trovagene
  • 07 Dec 2017 Pharmacokinetics data released by Trovagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top